The European digital health market faces fragmentation as member states apply divergent reimbursement criteria for prescription-based digital therapeutics (DTx).
Evidence Requirements
National health authorities require randomized controlled trial data tailored to local patient demographics, extending market entry timelines.
Payer Integration Challenges
Statutory health insurance schemes struggle to establish standardized pricing models for software updates and recurring feature rollouts.